Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 6/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28234278 | 0.88 | PI4KB (0.45) | PI4KBMAPTKDM4EHSD17B10CA1 | |
| SCHEMBL25305926 | 0.87 | PI4KB (0.44) | PI4KBMAPTKDM4EHSD17B10CA1 | |
| SCHEMBL11103983 | 0.86 | PI4KB (0.43) | PI4KBMAPTKDM4EHSD17B10CA1 | |
| Bicarbonate SCHEMBL10807004 | 0.83 | PI4KB (0.42) | PI4KBMAPTKDM4EHSD17B10CA1 | |
| Bicarbonate SCHEMBL10809756 | 0.83 | PI4KB (0.42) | PI4KBMAPTKDM4EHSD17B10CA1 | |
| SCHEMBL11108424 | 0.81 | PI4KB (0.43) | PI4KBMAPTKDM4EHSD17B10CA1 | |
| SCHEMBL6780955 | 0.81 | PI4KB (0.40) | PI4KBMAPTKDM4EHSD17B10CA1 | |
| SCHEMBL24435469 | 0.80 | ALDH1A1 (0.45) | PI4KBMAPTKDM4EHSD17B10LCK | |
| Bicarbonate SCHEMBL10810787 | 0.80 | PI4KB (0.42) | PI4KBMAPTKDM4EHSD17B10CA1 | |
| SCHEMBL24434778 | 0.80 | ALDH1A1 (0.45) | PI4KBMAPTKDM4EHSD17B10LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4734985-A1 | PREVENTION, INHIBITION OR TREATMENT OF CONDITIONS OR DISORDERS MEDIATED BY UROCANATE REDUCTASE | IMPLEXION PHARMA AB (SE) | 2026-05-06 | — | — | EP | disclosed |
| US-20250171434-A1 | SEC61 INHIBITORS AND USE THEREOF | ENODIA THERAPEUTICS SAS (FR) | 2025-05-29 | — | — | US | disclosed |
| EP-3930849-B1 | THIAZOLE DERIVATIVES AS PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20250042896-A1 | POLYCYCLIC COMPOUND AS CBL-B INHIBITOR | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2025-02-06 | — | — | US | disclosed |
| WO-2025026997-A1 | SUBSTITUED BICYCLIC HETEROCYCLIC YAP-TEAD AND/OR TAZ-TEAD INHIBITORS | MERCK PATENT GMBH (DE) | 2025-02-06 | — | — | WO | disclosed |
| EP-4486451-A1 | SEC61 INHIBITORS AND USE THEREOF | Kezar Life Sciences, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| WO-2025003469-A1 | PREVENTION, INHIBITION OR TREATMENT OF CONDITIONS OR DISORDERS MEDIATED BY UROCANATE REDUCTASE | IMPLEXION PHARMA AB (SE) | 2025-01-02 | — | — | WO | disclosed |
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2023-09-14 | — | — | US | disclosed |
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2023-09-14 | — | — | US | disclosed |
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2023-09-14 | — | — | US | disclosed |
| WO-2007093542-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007039512-A1 | NAPHTHYRIDIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078155-A1 | Naphthyridin derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-05 | — | — | US | disclosed |
| CN-1910151-A | Cyclic amine derivative with heteroaryl ring | SANKYO CO (JP) | 2007-02-07 | — | — | CN | disclosed |
| US-20060270706-A1 | Cyclic amine derivative having heteroaryl ring | SANKYO COMPANY, LTD. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1695962-A1 | CYCLIC AMINE DERIVATIVE HAVING HETEROARYL RING | Sankyo Company, Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| WO-2006076632-A1 | SUBSTITUTED HETEROARYL AMIDE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NFκB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060154973-A1 | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-13 | — | — | US | disclosed |
| US-6815459-B2 | USE IN PREVENTING VARIOUS MEDICAL DYSFUNCTIONS AND DISEASES ARISING FROM REACTIVE OXYGEN SPECIES, IN PARTICULAR STROKE, PARKINSON'S DISEASE, ALZHEIMER'S DISEASE; LIPID PEROXIDATION INHIBITION ACTIVITY | SAM-SUNG ELECTRONICS CO., LTD. (KR) | 2004-11-09 | — | — | US | disclosed |
| WO-2003010154-A1 | SELENO COMPOUNDS CONTAINING NITRONE MOIETY, THEIR PREPARATION AND THEIR THERAPEUTIC USES | SAMSUNG ELECTRONICS CO. LTD. (KR) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078155-A1 | Naphthyridin derivatives | GRM5, GRM3, GRM1 | PI4KB 4384/4885MAPT 2060/4885KDM4E 3285/4885 |
| US-20060154973-A1 | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | NFRKB, NFKB2, NFKB1 | PI4KB 675/4885MAPT 3065/4885KDM4E 2102/4885 |
| US-20250042896-A1 | POLYCYCLIC COMPOUND AS CBL-B INHIBITOR | CBLB, CBL, CBLC | PI4KB 489/4885MAPT 3095/4885KDM4E 1820/4885 |
| US-20060270706-A1 | Cyclic amine derivative having heteroaryl ring | F12, F2, H1-3 | PI4KB 1566/4885MAPT 4841/4885KDM4E 2289/4885 |
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | PI4KB 2085/4885MAPT 2824/4885KDM4E 4706/4885 |
| US-20250171434-A1 | SEC61 INHIBITORS AND USE THEREOF | SEC61B, SEC61A1, SEC61G | PI4KB 1541/4885MAPT 2444/4885KDM4E 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.